LysaKare (arginine;lysine)
- Region
- 🇪🇺 EU
- Active substance
- arginine;lysine
- Company
- Novartis Europharm Limited
- Status
- Authorised
- Therapeutic area
- Radiation Injuries
- CHMP opinion
- Wed 29 May 2019
- EU approval
- Thu 25 Jul 2019
- Application
- EMEA/H/C/004541
- ATC
- V03AF11
- Official record
- www.ema.europa.eu
Indication
LysaKare is indicated for reduction of renal radiation exposure during Peptide-Receptor Radionuclide Therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults.
Regulatory milestones
No milestones recorded in the last year.
Follow LysaKare
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.